AERI:NSD-Aerie Pharmaceuticals, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSD

Last Closing Price

USD 11.77

Change

+0.34 (+2.97)%

Market Cap

USD 0.53B

Volume

0.42M

Average Target Price

USD 27.60 (+134.49%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-30 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

+0.26 (+1.78%)

USD7.56B 26.81 7.09
MNTA Momenta Pharmaceuticals, Inc

-0.01 (-0.02%)

USD6.24B N/A N/A
PCRX Pacira BioSciences, Inc

+0.73 (+1.23%)

USD2.54B 870.20 73.37
CRON Cronos Group Inc

-0.04 (-0.79%)

USD1.79B 2.44 N/A
IRWD Ironwood Pharmaceuticals, Inc

-0.43 (-4.51%)

USD1.52B 15.26 12.72
APHA Aphria Inc

+0.09 (+2.07%)

USD1.25B 57.50 392.34
ATNX Athenex, Inc

-0.05 (-0.41%)

USD1.11B N/A N/A
SUPN Supernus Pharmaceuticals, Inc

-0.02 (-0.10%)

USD1.10B 9.18 5.84
PETQ PetIQ, Inc

+0.14 (+0.43%)

USD0.94B 134.36 111.60
AMPH Amphastar Pharmaceuticals, Inc

+0.12 (+0.64%)

USD0.88B 224.88 27.46

ETFs Containing AERI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -51.30% 30% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.30% 30% F 10% F
Trailing 12 Months  
Capital Gain -39.49% 41% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.49% 41% F 15% F
Trailing 5 Years  
Capital Gain -39.17% 55% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.17% 55% F 24% F
Average Annual (5 Year Horizon)  
Capital Gain 24.89% N/A N/A 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.89% N/A N/A 81% B-
Risk Return Profile  
Volatility (Standard Deviation) 90.01% N/A N/A 10% F
Risk Adjusted Return 27.65% N/A N/A 51% F
Market Capitalization 0.53B 74% C 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.03 27% F 21% F
Price / Cash Flow Ratio -3.54 67% D+ 70% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -164.34% 29% F 7% F
Return on Invested Capital -64.24% 30% F 15% F
Return on Assets -36.28% 18% F 9% F
Debt to Equity Ratio 113.00% 22% F 20% F
Technical Ratios  
Short Ratio 11.11 30% F 11% F
Short Percent 24.46% 11% F 8% F
Beta 0.82 83% B 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector